StockData
OKYO Pharma Ltd logo

OKYO Pharma Ltd (OKYO) stock

OKYONasdaqBiological Products, (No Diagnostic Substances)
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 20, 2026Score 1/30
$1.17−0.18 (-13.33%)

Close on Nov 16, 2026Market cap $61.40MP/E –Yield –

OKYO Pharma r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was $1.81M, down 19.7% from the year before. The highest annual figure on record is $8.24M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Mar 31, 2026$1.81M-19.7%
FY2025Mar 31, 2025$2.25M-72.7%
FY2024Mar 31, 2024$8.24M+30.1%
FY2023Mar 31, 2023$6.34M+293.8%
FY2022Mar 31, 2022$1.61M+362.1%
FY2021Mar 31, 2021$348.35K-32.8%
FY2020Mar 31, 2020$518.10K–

More OKYO Pharma figures

See a number that looks wrong?